Deutsch English Français

Contact

EP2406280

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2406280

EP2406280 - BIOLOGICAL MATERIALS AND USES THEREOF [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 20.03.2015 Database last updated on 28.09.2024
Most recent event Tooltip	24.04.2015	Change - lapse in a contracting state State(s) deleted from list of lapses: BE	published on 27.05.2015 [2015/22]
Applicant(s)	For all designated states Imperial Innovations Limited 52 Princes Gate, Exhibition Road South Kensington London SW7 2PG / GB
	[2014/16]
Former [2012/03]	For all designated states Imperial Innovations Limited Level 12 Electrical and Electronic Engineering Building Imperial College London SW7 2AZ / GB
Inventor(s)	01 / MIDWOOD, Kim, Suzanne Kennedy Institute of Rheumatology Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences University of Oxford, Roosevelt Drive, Headington Oxford OX3 7FY / GB
	02 / FOXWELL, Brian Maurice John deceased deceased / GB
	[2014/16]
Former [2014/15]	01 / MIDWOOD, Kim, Suzanne Department of Matrix Biology Kennedy Institute of Rheumatology Faculty of Medicine Imperial College, 65 Aspenlea Road London W6 8LH / GB
	02 / FOXWELL, Brian Maurice John deceased deceased / GB
Former [2012/03]	01 / MIDWOOD, Kim, Suzanne Department of Matrix Biology Kennedy Institute of Rheumatology Faculty of Medicine Imperial College, 65 Aspenlea Road London W6 8LH / GB
Representative(s)	Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB
	[N/P]
Former [2014/20]	Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham, NG1 5GG / GB
Former [2013/37]	Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB
Former [2012/03]	Wainwright, Jane Helen Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB
Application number, filing date	10722160.8	15.03.2010
	WO2010GB00460
Priority number, date	GB20090004355	13.03.2009 Original published format: GB 0904355
	[2012/03]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010103289
	Date:	16.09.2010
	Language:	EN
	[2010/37]
	Type:	A1 Application with search report
	No.:	EP2406280
	Date:	18.01.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 16.09.2010 takes the place of the publication of the European patent application.
	[2012/03]
	Type:	B1 Patent specification
	No.:	EP2406280
	Date:	14.05.2014
	Language:	EN
	[2014/20]
Search report(s)	International search report - published on:	EP	16.09.2010
Classification	IPC:	C07K14/47, C07K14/78, C07K16/18, C12N15/113	[2013/48]
	CPC:	C07K14/47 (EP,US); A61P1/04 (EP); A61P11/00 (EP); A61P11/06 (EP); A61P17/02 (EP); A61P17/06 (EP); (+) A61P19/02 (EP); A61P25/00 (EP); A61P29/00 (EP); A61P3/10 (EP); A61P31/00 (EP); A61P35/00 (EP); A61P37/00 (EP); A61P43/00 (EP); A61P9/10 (EP); C07K14/4713 (EP,US); C07K14/78 (EP,US); C07K16/18 (EP,US); C07K2317/34 (EP,US); C07K2317/76 (EP,US) (-)
	Former IPC [2012/03]	C07K14/47, C12N15/113
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/03]
Extension states	AL	Not yet paid
	BA	Not yet paid
	ME	Not yet paid
	RS	Not yet paid
Title	German:	BIOLOGISCHE MATERIALIEN UND VERWENDUNGEN DAVON	[2012/03]
	English:	BIOLOGICAL MATERIALS AND USES THEREOF	[2012/03]
	French:	MATÉRIELS BIOLOGIQUES ET LEURS UTILISATIONS	[2012/03]
Entry into regional phase	10.10.2011	National basic fee paid
	10.10.2011	Designation fee(s) paid
	10.10.2011	Examination fee paid
Examination procedure	10.10.2011	Examination requested [2012/03]
	13.04.2012	Amendment by applicant (claims and/or description)
	01.08.2012	Despatch of a communication from the examining division (Time limit: M06)
	31.01.2013	Reply to a communication from the examining division
	25.02.2013	Despatch of a communication from the examining division (Time limit: M04)
	14.06.2013	Reply to a communication from the examining division
	03.12.2013	Communication of intention to grant the patent
	02.04.2014	Fee for grant paid
	02.04.2014	Fee for publishing/printing paid
	02.04.2014	Receipt of the translation of the claim(s)
Divisional application(s)	EP14162944.4 / EP2754668
	EP18170211.9 / EP3392269
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 01.08.2012
Opposition(s)	17.02.2015	No opposition filed within time limit [2015/17]
Fees paid	Renewal fee
	29.03.2012	Renewal fee patent year 03
	11.03.2013	Renewal fee patent year 04
	12.03.2014	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	deleted
	[2015/22]
Former [2015/08]	BE	14.05.2014
Cited in	International search	[X]WO2008154008 (SCRIPPS RESEARCH INST [US], et al) [X] 1-3,7-10,25,36-41 * page 41 *;
		[X]WO2005009366 (CORNELL RES FOUNDATION INC [US], et al) [X] 15,47-50 * pages 41-49 *;
		[I] - NAKAHARA HIROKI ET AL, "Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse.", EUROPEAN JOURNAL OF IMMUNOLOGY DEC 2006 LNKD- PUBMED:17125141, (200612), vol. 36, no. 12, ISSN 0014-2980, pages 3334 - 3345, XP002594137 [I] 1-23,25-50 * the whole document * DOI: http://dx.doi.org/10.1002/EJI.200636271
		[XD] - CHIQUET-EHRISMANN RUTH ET AL, "Tenascins: regulation and putative functions during pathological stress.", THE JOURNAL OF PATHOLOGY JUL 2003 LNKD- PUBMED:12845616, (200307), vol. 200, no. 4, ISSN 0022-3417, pages 488 - 499, XP002594134 [XD] 1-8,10-13,25 * the whole document * DOI: http://dx.doi.org/10.1002/PATH.1415
		[X] - TAVAZOIE SOHAIL F ET AL, "Endogenous human microRNAs that suppress breast cancer metastasis.", NATURE 10 JAN 2008 LNKD- PUBMED:18185580, (20080110), vol. 451, no. 7175, ISSN 1476-4687, pages 147 - 152, XP002594135 [X] 1-6,10,25 * the whole document * DOI: http://dx.doi.org/10.1038/NATURE06487
		[X] - CALVO A ET AL, "Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.", ONCOGENE 11 SEP 2008 LNKD- PUBMED:18504437, (20080911), vol. 27, no. 40, ISSN 1476-5594, pages 5373 - 5384, XP002594136 [X] 1-6,10,25 * the whole document * DOI: http://dx.doi.org/10.1038/ONC.2008.155
		[IDP] - MIDWOOD KIM ET AL, "Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.", NATURE MEDICINE JUL 2009 LNKD- PUBMED:19561617, (200907), vol. 15, no. 7, ISSN 1546-170X, pages 774 - 780, XP002594138 [IDP] 1-50 * the whole document * DOI: http://dx.doi.org/10.1038/NM.1987
	by applicant	- HUTVAGNER; ZAMORE, CURR. OPIN. GENETICS AND DEVELOPMENT, (2002), vol. 12, pages 225 - 232
		- BERNSTEIN, NATURE, (2001), vol. 409, pages 363 - 366
		- HAMMOND ET AL., NAT. REV. GEN., (2001), vol. 2, pages 110 - 119
		- SHARP, GENES. DEV., (2001), vol. 15, pages 485 - 90
		- TUSCHL, CHEM. BIOCHEM., (2001), vol. 2, pages 239 - 245
		- CULLEN, NAT. IMMUNOL., (2002), vol. 3, pages 597 - 599
		- BRANTL, BIOCHEM. BIOPHYS ACT., (2002), vol. 1575, pages 15 - 25
		- TUSCHL, CHEMBIOCHEM., vol. 2, pages 239 - 245
		- LUFT, J MOL MED, (1998), vol. 76, pages 75 - 6
		- KRONENWETT ET AL., BLOOD, (1998), vol. 91, pages 852 - 62
		- RAJUR ET AL., BIOCONJUG CHEM, (1997), vol. 8, pages 935 - 40
		- LAVIGNE ET AL., BIOCHEM BIOPHYS RES COMMUN, (1997), vol. 237, pages 566 - 71
		- AOKI ET AL., BIOCHEM BIOPHYS RES COMMUN, (1997), vol. 231, pages 540 - 5
		- WALTON ET AL., BIOTECHNOL BIOENG, (1999), vol. 65, pages 1 - 9
		- MATVEEVA ET AL., NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 1374 - 1375
		- HOLMLUND ET AL., CURR OPIN MOL THER, (1999), vol. 1, pages 372 - 85
		- GERWITZ, CURR OPIN MOL THER, (1999), vol. 1, pages 297 - 306
		- UNO ET AL., CANCER RES, (2001), vol. 61, pages 7855 - 60
		- WITTERS ET AL., BREAST CANCER RES TREAT, (1999), vol. 53, pages 41 - 50
		- FRANKEL ET AL., J NEUROSURG, (1999), vol. 91, pages 261 - 7
		- AGRAWAL ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 7079 - 7083
		- SARIN ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 7448 - 7451
		- AGRAWAL ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 7790 - 7794
		- LEITHER ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 3430 - 3434
		- SHAW ET AL., NUCLEIC ACIDS RES., (1991), vol. 19, pages 747 - 750
		- AGRAWAL; TANG, TETRAHEDRON LETTERS, (1990), vol. 31, pages 7541 - 7544
		- AGRAWAL; GOODCHILD, TETRAHEDRON LETTERS, (1987), vol. 28, page 3539
		- NIELSEN ET AL., TETRAHEDRON LETTERS, (1988), vol. 29, page 2911
		- JAGER ET AL., BIOCHEMISBY, (1988), vol. 27, page 7237
		- UZNANSKI ET AL., TETRAHEDRON LETTERS, (1987), vol. 28, page 3401
		- BANNWARTH, HELV. CHIM. ACTA., (1988), vol. 71, page 1517
		- CROSSTICK; VYLE, TETRAHEDRON LETTERS, (1989), vol. 30, page 4693
		- AGRAWAL ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 1401 - 1405
		- AGRAWAL ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, no. 17, pages 7595 - 7599
		- TANG ET AL., NUCL. ACIDS RES., (1993), vol. 21, pages 2729 - 2735
		- PLANT ET AL., ANALYT BIOCHEM, (1995), vol. 226, no. 2, pages 342 - 348
		- FIELDS; SONG, NATURE, (1989), vol. 340, pages 245 - 246
		- ORLANDI. ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1989), vol. 86, pages 3833 - 3837
		- WINTER ET AL., NATURE, (1991), vol. 349, pages 293 - 299
		- KOHLER ET AL., NATURE, (1975), vol. 256, page 4950497
		- KOZBOR ET AL., J. IMMUNOL. METHODS, (1985), vol. 81, pages 31 - 42
		- COTE ET AL., PROC. NATL. ACAD. SCI. USA, (1983), vol. 80, pages 2026 - 2030
		- COLE ET AL., MOL. CELL. BIOL., (1984), vol. 62, pages 109 - 120
		- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
		- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
		- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
		- REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
		- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 15361
		- HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
		- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
		- BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, pages 86 - 95
		- DASS, J PHARM PHARMACOL., (2002), vol. 54, no. 1, pages 3 - 27
		- DASS, DRUG DELIV., (2001), vol. 8, no. 4, pages 191 - 213
		- LEBEDEVA ET AL., EUR J PHARM BIOPHARM., (2000), vol. 50, no. 1, pages 101 - 19
		- PIERCE ET AL., MINI REV MED CHEM., (2005), vol. 5, no. 1, pages 41 - 55
		- LYSIK; WU-PONG, J PHARM SCI., (2003), vol. 2, no. 8, pages 1559 - 73
		- DASS, BIOTECHNOL APPL BIOCHEM., (2004), vol. 40, no. 2, pages 113 - 22
		- MEDINA, CURR PHARM DES., (2004), vol. 10, no. 24, pages 2981 - 9
		- THOMPSON ET AL., NUC. ACID RES., (1994), vol. 22, pages 4673 - 4680
		- SMOLEN, J.S.; MAINI, R.N., "Interleukin-6: a new therapeutic target", ARTHRITIS RES HIER, (2006), vol. 8, no. 2, page S5
		- WILLIAMS, R.O.; PALEOLOG, E.; FELDMANN, M., "Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases", CURR OPIN PHARMACOL7, (2007), doi:doi:10.1016/j.coph.2007.06.001, pages 412 - 417, XP022213373 DOI: http://dx.doi.org/10.1016/j.coph.2007.06.001
		- BRENTANO, F.; KYBURZ, D.; SCHORR, 0.; GAY, R.; GAY, S., "The role of Toll-like receptor signalling in the pathogenesis of arthritis", CELL IMMUNOL, (2005), vol. 233, pages 90 - 96
		- MATZINGER, P., "The danger model: a renewed sense of self", SCIENCE, (2002), vol. 296, pages 301 - 305
		- BIANCHI, M.E. DAMPS, "PAMPs and alarmins: all we need to know about danger", J LEUKOC BIOL, (2007), vol. 81, pages 1 - 5
	- GORDON, S., "Pattern recognition receptors: doubling up for the innate immune response", CEL, (2002), vol. 111, pages 927 - 930
	- MEDZHITOV, R.; JANEWAY, C.A., JR., "Decoding the patterns of self and nonself by the innate immune system", SCIENCE, (2002), vol. 296, pages 298 - 300
	- RADSTAKE, T.R. ET AL., "Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma", ARTHRITIS RHEUM, (2004), vol. 50, doi:doi:10.1002/art.20678, pages 3856 - 3865, XP002565781 DOI: http://dx.doi.org/10.1002/art.20678
	- ROELOFS, M.F. ET AL., "The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells", ARTHRITIS RHEUM, (2005), vol. 52, pages 2313 - 2322
	- SACRE, S.M. ET AL., "The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis", AM J PATHOL, (2007), vol. 170, pages 518 - 525
	- CHOE, J.Y.; CRAIN, B.; WU, S.R.; CORR, M., "Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling", J EXP MED, (2003), vol. 197, doi:doi:10.1084/jem.20021850, pages 537 - 542, XP002309814 DOI: http://dx.doi.org/10.1084/jem.20021850
	- LEE, E.K.; KANG, S.M.; PAIK, D.J.; KIM, J.M.; YOUN, J., "Essential roles of Toll-like receptor-4 signaling in arthritis induced by type II collagen antibody and LPS", INT IMMUNOL, (2005), vol. 17, pages 325 - 333
	- ABDOLLAHI-ROODSAZ, S. ET AL., "Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis", ARTHRITIS RHEUM, (2007), vol. 56, doi:doi:10.1002/art.22848, pages 2957 - 2967, XP002477009 DOI: http://dx.doi.org/10.1002/art.22848
	- VANAGS, D. ET AL., "Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial", LANCET, (2006), vol. 368, doi:doi:10.1016/S0140-6736(06)69210-6, pages 855 - 863, XP025093290 DOI: http://dx.doi.org/10.1016/S0140-6736(06)69210-6
	- CHIQUET-EHRISMANN, R.; CHIQUET, M., "Tenascins: regulation and putative functions during pathological stress", J PATHOI, (2003), vol. 200, doi:doi:10.1002/PATH.1415, pages 488 - 499, XP002594134 DOI: http://dx.doi.org/10.1002/PATH.1415
	- CUTOLO, M.; PICASSO, M.; PONASSI, M.; SUN, M.Z.; BALZA, E., "Tenascin and fibronectin distribution in human normal and pathological synovium", J RHEUMATOL, (1992), vol. 19, pages 1439 - 1447
	- MCCACHREN, S.S.; LIGHTNER, V.A., "Expression of human tenascin in synovitis and its regulation by interleukin-1", ARTHRITIS RHEUM, (1992), vol. 35, pages 1185 - 1196
	- SALTER, D.M., "Tenascin is increased in cartilage and synovium from arthritic knees", BR J RHEUMATOL, (1993), vol. 32, pages 780 - 786, XP009183530 DOI: http://dx.doi.org/10.1093/rheumatology/32.9.780
	- CHEVALIER, X.; GROULT, N.; LARGET-PIET, B.; ZARDI, L.; HORNEBECK, W., "Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis", ARTHRITIS RHEUM, (1994), vol. 37, pages 1013 - 1022
	- HASEGAWA, M. ET AL., "Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis", J ORTHOP RES, (2007), vol. 25, doi:doi:10.1002/jor.20366, pages 563 - 568, XP055062003 DOI: http://dx.doi.org/10.1002/jor.20366
	- OREND, G., "Potential oncogenic action of tenascin-C in tumorigenesis", INT J BIOCHEM CELL BIOL, (2005), vol. 37, doi:doi:10.1016/j.biocel.2004.12.002, pages 1066 - 1083, XP005282521 DOI: http://dx.doi.org/10.1016/j.biocel.2004.12.002
	- BRACKERTZ, D.; MITCHELL, G.F.; MACKAY, I.R., "Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice", ARTHRITIS RHEUM, (1977), vol. 20, pages 841 - 850
	- BRENNAN, F.M.; CHANTRY, D.; JACKSON, A.; MAINI, R.; FELDMANN, M., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", LANCET, (1989), vol. 2, pages 244 - 247
	- SMILEY, S.T.; KING, J.A.; HANCOCK, W.W., "Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4", J IMMUNOL, (2001), vol. 167, pages 2887 - 2894
	- FITZGERALD, K.A.; ROWE, D.C.; GOLENBOCK, D.T., "Endotoxin recognition and signal transduction by the TLR4/MD2-complex", MICROBES INFECT, (2004), vol. 6, doi:doi:10.1016/j.micinf.2004.08.015, pages 1361 - 1367, XP004676561 DOI: http://dx.doi.org/10.1016/j.micinf.2004.08.015
	- JIANG, Z. ET AL., "CD14 is required for MyD88-independent LPS signaling", NAT IMMUNOL, (2005), vol. 6, doi:doi:10.1038/ni1207, pages 565 - 570, XP002519138 DOI: http://dx.doi.org/10.1038/ni1207
	- COATS, S.R.; DO, C.T.; KARIMI-NASER, L.M.; BRAHAM, P.H.; DARVEAU, RP., "Antagonistic lipopolysaccharides block E. coli lipopolysaccharide function at human TLR4 via interaction with the human MD-2 lipopolysaccharide binding site", CELL MICROBIOL, (2007), vol. 9, pages 1191 - 1202
	- SIRI, A. ET AL., "Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies", NUCLEIC ACIDS RES, (1991), vol. 19, pages 525 - 531, XP000919423
	- GONDOKARYONO, S.P. ET AL., "The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4", J LEUKOC BIOL, (2007), vol. 82, pages 657 - 665
	- TAYLOR, K.R. ET AL., "Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2", J BIOL CHEM, (2007), vol. 282, pages 18265 - 18275
	- KIM, H.M. ET AL., "Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran", CELL, (2007), vol. 130, doi:doi:10.1016/j.cell.2007.08.002, pages 906 - 917, XP008134128 DOI: http://dx.doi.org/10.1016/j.cell.2007.08.002
	- SCHAEFER, L. ET AL., "The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages", J CLIN INVEST, (2005), vol. 115, pages 2223 - 2233
	- FOELL, D.; WITTKOWSKI, H.; ROTH, J., "Mechanisms of disease: a 'DAMP' view of inflammatory arthritis", NAT CLIN PRACT RHEUMATOL, (2007), vol. 3, pages 382 - 390
	- TANIGUCHI, N. ET AL., "High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine", ARTHRITIS RHEUM, (2003), vol. 48, doi:doi:10.1002/art.10859, pages 971 - 981, XP055003536 DOI: http://dx.doi.org/10.1002/art.10859
	- PULLERITS, R. ET AL., "High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis", ARTHRITIS RHEUM, (2003), vol. 48, pages 1693 - 1700
	- KOKKOLA, R. ET AL., "Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity", ARTHRITIS RHEUM, (2003), vol. 48, doi:doi:10.1002/art.11161, pages 2052 - 2058, XP001205688 DOI: http://dx.doi.org/10.1002/art.11161
	- GUTOWSKI, N.J.; NEWCOMBE, J.; CUZNER, M.L., "Tenascin-R and C in multiple sclerosis lesions: relevance to extracellular matrix remodelling", NEUROPATHOL APPL NEUROBIOL, (1999), vol. 25, pages 207 - 214
	- AMIN, K. ET AL., "Inflammation and structural changes in the airways of patients with primary Sjogren's syndrome", RESPIR MED, (2001), vol. 95, pages 904 - 910
	- LOOTS, M.A. ET AL., "Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds", J INVEST DERMATOL, (1998), vol. 111, pages 850 - 857
	- LANGE, K. ET AL., "Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization", CANCER RES, (2007), vol. 67, pages 6163 - 6173
	- SAGA, Y.; YAGI, T.; IKAWA, Y.; SAKAKURA, T.; AIZAWA, S., "Mice develop normally without tenascin", GENES DEV, (1992), vol. 6, pages 1821 - 1831
	- HOSHINO, K. ET AL., "Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product", J IMMUNOL, (1999), vol. 162, pages 3749 - 3752, XP002221244
	- TAKEUCHI, 0. ET AL., "Differential roles of TLR2 and TLR4 in recognition of gram- negative and gram-positive bacterial cell wall components", IMMUNITY, (1999), vol. 11, doi:doi:10.1016/S1074-7613(00)80119-3, pages 443 - 451, XP002927803 DOI: http://dx.doi.org/10.1016/S1074-7613(00)80119-3
	- KEYSTONE, E.C.; SCHORLEMMER, H.U.; POPE, C.; ALLISON, A.C., "Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement", ARTHRITIS RHEUM, (1977), vol. 20, pages 1396 - 1401
	- VAN LENT, P.L. ET AL., "Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation", ARTHRITIS RHEUM, (2006), vol. 54, pages 3868 - 3877
	- FOXWELL, B. ET AL., "Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent", PROC NATL ACAD SCI U S A, (1998), vol. 95, doi:doi:10.1073/pnas.95.14.8211, pages 8211 - 8215, XP002098099 DOI: http://dx.doi.org/10.1073/pnas.95.14.8211
	- KURT-JONES, E.A. ET AL., "Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity", J ENDOTOXIN RES, (2004), vol. 10, doi:doi:10.1179/096805104225006516, pages 419 - 424, XP009157321 DOI: http://dx.doi.org/10.1179/096805104225006516
	- TODARO, G.J.; GREEN, H., "Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines", J CELL BIOL, (1963), vol. 17, pages 299 - 313
	- BUTLER, D.M.; MALFAIT, A.M.; MAINI, R.N.; BRENNAN, F.M.; FELDMANN, M., "Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis", EUR J IMMUNOL, (1999), vol. 29, pages 2205 - 2212
	- HO, S.N.; HUNT, H.D.; HORTON, R.M.; PULLEN, J.K.; PEASE, L.R., "Site-directed mutagenesis by overlap extension using the polymerase chain reaction", GENE, (1989), vol. 77, doi:doi:10.1016/0378-1119(89)90358-2, pages 51 - 59, XP023544945 DOI: http://dx.doi.org/10.1016/0378-1119(89)90358-2
	- CLARK, R.A.; ERICKSON, H.P.; SPRINGER, T.A., "Tenascin supports lymphocyte rolling", J CELL BIOL, (1997), vol. 137, doi:doi:10.1083/jcb.137.3.755, pages 755 - 765, XP055221772 DOI: http://dx.doi.org/10.1083/jcb.137.3.755
	- EI-KAREF, A. ET AL., "Deficiency of tenascin-C attenuates liver fibrosis in immune- mediated chronic hepatitis in mice", J PATHOL, (2007), vol. 211, pages 86 - 94
	- LOIKE, J.D.; CAO, L.; BUDHU, S.; HOFFMAN, S.; SILVERSTEIN, S.C., "Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins", J IMMUNOL, (2001), vol. 166, pages 7534 - 7542, XP002304209
	- TALTS, J.F.; WIRL, G.; DICTOR, M.; MULLER, W.J.; FASSLER, R., "tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer", J CELL SCI, (1999), vol. 112, no. 12, pages 1855 - 1864
	- JONES, MATRIX BIOL., (2000), vol. 19, pages 581 - 96
	- HARAND, EXPERT REVIEW OF VACCINES, (2009), vol. 8, pages 293 - 298
	- MCLNTYRE, BMC BIOTECHNOL., (2006), vol. 6, page 1
	- PADDISON, GENES DEV., (2002), vol. 16, no. 8, pages 948 - 58
	- ANDREAKOS, BLOOD, (2004), vol. 103, pages 2229 - 37
	- GOH, F.G.; PICCININI, A.M.; KRAUSGRUBER, T.; UDALOVA, I.A.; MIDWOOD, K.S., "Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation", J IMMUNOL, (2010), vol. 184, doi:doi:10.4049/jimmunol.0903359, pages 2655 - 2662, XP055061294 DOI: http://dx.doi.org/10.4049/jimmunol.0903359
	- MIDWOOD, K. ET AL., "Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease", NAT MED, (2009), vol. 15, doi:doi:10.1038/NM.1987, pages 774 - 780, XP002594138 DOI: http://dx.doi.org/10.1038/NM.1987
	- LAFLEUR, D.W. ET AL., "Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain", J BIOL CHEM, (1997), vol. 272, pages 32798 - 32803
	- TAYLOR, P.C.; FELDMANN, M., "Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis", NAT REV RHEUMATOL, (2009), vol. 5, pages 578 - 582, XP009146864
	- YOKOYAMA, K.; ERICKSON, H.P.; IKEDA, Y.; TAKADA, Y., "Identification of amino acid sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical for binding to integrin alpha vbeta 3", J BIOL CHEM, (2000), vol. 275, pages 16891 - 16898

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p